20/20 Biolabs Inc (NASDAQ:AIDX) Short Interest Up 126.7% in June

20/20 Biolabs Inc (NASDAQ:AIDX) saw a large growth in short interest during the month of June. As of June 15th, there was short interest totaling 291,990 shares, a growth of 126.7% from the May 31st total of 128,775 shares. Based on an average trading volume of 2,692,121 shares, the short-interest ratio is presently 0.1 days. Approximately 2.8% of the shares of the stock are short sold.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on AIDX shares. Weiss Ratings initiated coverage on 20/20 Biolabs in a research report on Thursday, May 14th. They set a “sell (e-)” rating on the stock. Maxim Group began coverage on 20/20 Biolabs in a report on Monday, May 11th. They set a “buy” rating and a $5.00 target price for the company. Finally, Wall Street Zen raised shares of 20/20 Biolabs to a “hold” rating in a report on Saturday, March 14th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $5.00.

20/20 Biolabs Price Performance

NASDAQ AIDX traded down $0.03 on Monday, reaching $0.57. 68,034 shares of the company’s stock traded hands, compared to its average volume of 658,713. 20/20 Biolabs has a fifty-two week low of $0.54 and a fifty-two week high of $50.00. The business has a 50 day moving average of $1.13.

20/20 Biolabs (NASDAQ:AIDX) last announced its quarterly earnings results on Wednesday, May 20th. The company reported ($0.28) earnings per share for the quarter. The company had revenue of $0.35 million during the quarter.

20/20 Biolabs Company Profile

We develop and commercialize AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. We offer two families of lab tests, both under our OneTest brand: (i) OneTest for Cancer, a multi-cancer early detection, or MCED, blood test which has been our primary commercial focus and source of revenues since we wound down our COVID-19 testing business, and (ii) OneTest for Longevity, which measures inflammatory biomarkers, that we expect to launch in the first half of 2026.